

BEST AVAILABLE COPY

Dkt. 57746-A-PCT-US/JPW/FIB

ASSIGNMENT

In consideration of One Dollar (\$1.00), and other good and valuable considerations, the receipt of which is hereby acknowledged, we, the undersigned,

Peter Buhlmayer, residing at Haugstrasse 18, CH 4144, Arlesheim, Switzerland;

Heinrich Rueger, residing at Allemannenweg 6, CH 4112 Fluh, Switzerland;

Yasuhiko Yamaguchi, residing at 70 Point Arrowhead Road, Guilford, CT 06437, United States of America; and

Walter Schilling, residing at Im Muspenacker 204, CH-4204 Himmelried, Switzerland

Hereby sell, assign and transfer to Novartis AG, a corporation of Switzerland, having a place of business at Klybeckstrasse 141, CH-4002 Basel, Switzerland, its successors, assigns and legal representatives, the entire right, title and interest for all countries, in and to any and all inventions which are disclosed and claimed, and any and all inventions which are disclosed but not claimed, in the application for United States Patent, which has been executed by the undersigned on March 13, 2002, March 13, 2002, , 2002, and March 13, 2002 and is entitled

SELECTIVE NPY (Y5) ANTAGONISTS

(United States Serial No. 10/019,881, filed December 27, 2001 a 371 national stage of PCT International Application No. PCT/US00/11004, filed April 21, 2000 on behalf of Synaptic Pharmaceutical Corporation and Novartis AG, a continuation-in-part and claiming priority of U.S. Serial No. 09/343,636, filed June 30, 1999; U.S. Serial No. 09/343,633, filed June 30, 1999; and U.S. Serial No. 09/343,993, filed June 30, 1999)

and in and to said application and all divisional, continuing,

substitute, renewal, reissue, and all other applications for U.S. Letters Patent or other related property rights in any and all foreign countries which have been or shall be filed on any of said inventions disclosed in said application; and in and to all original and reissued patents or related foreign documents which have been or shall be issued on said inventions;

Authorize and request the Commissioner of Patents of the United States to issue to said Assignee, the corporations above named, their successors, assigns and legal representatives, in accordance with this assignment, any and all United States Letters Patent on said inventions or any of them disclosed in said application;

Agree that said Assignee may apply for and receive foreign letters Patent or rights of any other kind for said inventions, or any of them; and may claim, in applications for said foreign letters Patent or other rights, the priority of the aforesaid United States patent application under the provisions of the International Convention of 1883 and later modifications thereof, under the Patent Cooperation Treaty under the European Patent Convention or under any other available international agreement; and that, when requested, without charge to, but at the expense of, said Assignee, its successors, assigns and legal representatives, to carry out in good faith the intent and purpose of this assignment, the undersigned or the undersigned's executors or administrators will, for the United States and all foreign countries, execute all divisional, continuing, substitute, renewal, reissue, and all other patent applications or other documents on any and all said inventions; execute all rightful oaths, assignments, powers of attorney and other papers; communicate to

3

said Assignee, its successors, assigns and representatives, all facts known and documents available to the undersigned relating to said inventions and the history thereof; testify in all legal proceedings; and generally do everything possible which said Assignee, its successors, assigns or representatives shall consider desirable for aiding in securing, maintaining and enforcing proper patent protection for said inventions and for vesting title to said inventions and all applications for patents or related foreign rights and all patents on said inventions, in said Assignee, its successors, assigns and legal representatives; and

Covenant with said Assignee, its successors, assigns and legal representatives that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by the undersigned, and that full right to convey the same as herein expressed is possessed by the undersigned.

Peter Buhlmayer (L.S.)

Date: April 8 2002 Peter Buhlmayer

Witness: _____

10/27/2004 13:50 FAX 212 753 6237
10/22/2004 14:02 FAX 212 753 6237

DARBY & DARBY PC
DARBY & DARBY PC

008/012
005/005

Heinrich Rueger [L.S.]

Date: 8 April 2002 2002

Heinrich Rueger

Witness: _____

[L.S.]

Date: _____ 2002

Yasuchika Yamaguchi

Witness: _____

Walter Schilling
Walter Schilling [L.S.]

Date: 8 April 2002 2002

Walter Schilling

Witness: _____

pkt. 57746-A-PCT-US/JPW/FHB

ASSIGNMENT

In consideration of One Dollar (\$1.00), and other good and valuable considerations, the receipt of which is hereby acknowledged, we, the undersigned,

Peter Buhlmayer, residing at Bungstrasse 18, CH 4144, Arlesheim, Switzerland;
Heinrich Rueger, residing at Almannenweg 6, CH 4112 Flub, Switzerland;
Yasuchika Yamaguchi, residing at 70 Point Arrowhead Road, Guilford, CT 06437, United States of America; and
Walter Schilling, residing at Im Muspenacker 204, CH-4204 Hammelried, Switzerland

hereby will, assign and transfer to Novartis AG, a corporation of Switzerland, having a place of business at Klybeckstrasse 141, CH-4000 Basel, Switzerland, its successors, assigns and legal representatives, the entire right, title and interest for all countries, in and to any and all inventions which are disclosed and claimed, and any and all inventions which are disclosed but not claimed, in the application for United States Patent, which has been executed by the undersigned on March 13, 2002, March 13, 2002, April 2, 2002, and March 13, 2002 and is entitled

SELECTIVE NPY (YS) ANTAGONISTS

(United States Serial No. 10/019,881, filed December 27, 2001 a national stage of PCT International Application No. PCT/US00/11004, filed April 21, 2000 on behalf of Synaptic Pharmaceutical Corporation and Novartis AG, a continuation-in-part and claiming priority of U.S. Serial No. 09/343,635, filed June 30, 1999; U.S. Serial No. 09/343,633, filed June 30, 1999; and U.S. Serial No. 09/343,993, filed June 30, 1999)

and in and to said application and all divisional, continuing,

2

substitute, renewal, reissue, and all other applications for U.S. Letters Patent or other related property rights in any and all foreign countries which have been or shall be filed on any of said inventions disclosed in said application; and in and to all original and reissued patents or related foreign documents which have been or shall be issued on said inventions;

Authorize and request the Commissioner of Patents of the United States to issue to said Assignee, the corporations above named, their successors, assigns and legal representatives, in accordance with this assignment, any and all United States Letters Patent on said inventions or any of them disclosed in said application;

Agree that said Assignee may apply for and receive foreign Letters Patent or rights of any other kind for said inventions, or any of them; and may claim, in applications for said foreign Letters Patent or other rights, the priority of the aforesaid United States patent application under the provisions of the International Convention of 1883 and later modifications thereto, under the Patent Cooperation Treaty under the European Patent Convention or under any other available international agreement; and that, when requested, without charge to, but at the expense of, said Assignee, its successors, assigns and legal representatives, to carry out in good faith the intent and purpose of this assignment, the undersigned or the undersigned's executors or administrators will, for the United States and all foreign countries, execute all divisional, continuing, substitute, renewal, reissue, and all other patent applications or other documents on any and all said inventions; execute all rightful oaths, assignments, powers of attorney and other papers; communicate to

10/27/2004 13:51 FAX 212 753 6237
10/22/2004 14:02 FAX 212 753 6237

DARBY & DARBY PC
DARBY & DARBY PC

011/012
008/009

3

said Assignee, its successors, assigns and representatives, all facts known and documents available to the undersigned relating to said inventions and the history thereof; testify in all legal proceedings; and generally do everything possible which said Assignee, its successors, assigns or representatives shall consider desirable for aiding in securing, maintaining and enforcing proper patent protection for said inventions and for vesting title to said inventions and all applications for patents or related foreign rights and all patents on said inventions, in said Assignee, its successors, assigns and legal representatives; and

Covenant with said Assignee, its successors, assigns and legal representatives that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by the undersigned, and that full right to convey the same as herein expressed is possessed by the undersigned.

(U.S.)

Date: _____ 2002 Peter Buhlmayer
Witness: _____

10/27/2004 13:51 FAX 212 753 6237

DARBY & DARBY PC

012/012
009/009

Date: _____ 2002

Heinrich Rueger

[L. S.]

Witness: _____

Heinrich Rueger

DATE: 12th / Apr / 2003

Yasutomo Yamaguchi

14.21

Witness: J. G.

718 ~~14-2860000~~ 84
Dinner, (T 5602), West

Yasutaka Yamaguchi

Environ Monit Assess (2002) 80:323–332

Walter Schilling

(19, 3-1)

WILHELM, *Die Wissenschaften* 1998. 10. 10. 100-110. © 1998 Walter de Gruyter GmbH & Co. KG, Berlin

A horizontal line consisting of five short, evenly spaced black dashes.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER: Blurred**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.